AIM: To investigate whether selenomethionine (SLM) reduces mucositis incidence in patients with head and neck squamous cell cancer (HNSCC) undergoing concurrent chemoradiation (CRT). METHODS: In this multi-institutional, randomized, double-blind phase II trial, patients with Stage III or IV HNSCC received SLM 3600 μg/m(2) or placebo twice daily for 7 d prior to CRT, once daily during CRT, and daily for 3 wk following CRT. CRT consisted of 70 Gy at 2 Gy per fraction with cisplatin 100 mg/m(2) IV on days 1, 22, and 43. RESULTS:Eighteen patients were randomized, 10 received SLM, and there were no differences in baseline factors. There was no difference in mucositis or patient-reported side effects between groups. There was no difference in overall or relapse-free survival at 12 mo. CONCLUSION: Addition of SLM to CRT for HNSCC was well-tolerated but did not lower the incidence of severe mucositis or improve quality of life or survival outcomes.
RCT Entities:
AIM: To investigate whether selenomethionine (SLM) reduces mucositis incidence in patients with head and neck squamous cell cancer (HNSCC) undergoing concurrent chemoradiation (CRT). METHODS: In this multi-institutional, randomized, double-blind phase II trial, patients with Stage III or IV HNSCC received SLM 3600 μg/m(2) or placebo twice daily for 7 d prior to CRT, once daily during CRT, and daily for 3 wk following CRT. CRT consisted of 70 Gy at 2 Gy per fraction with cisplatin 100 mg/m(2) IV on days 1, 22, and 43. RESULTS: Eighteen patients were randomized, 10 received SLM, and there were no differences in baseline factors. There was no difference in mucositis or patient-reported side effects between groups. There was no difference in overall or relapse-free survival at 12 mo. CONCLUSION: Addition of SLM to CRT for HNSCC was well-tolerated but did not lower the incidence of severe mucositis or improve quality of life or survival outcomes.
Entities:
Keywords:
Chemoprotective; Chemotherapy; Radiation therapy; Radioprotector; Selenium; Squamous cell cancer
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J Büntzel; D Riesenbeck; M Glatzel; R Berndt-Skorka; T Riedel; R Mücke; K Kisters; K G Schönekaes; U Schäfer; F Bruns; O Micke Journal: Anticancer Res Date: 2010-05 Impact factor: 2.480
Authors: Jean Bourhis; Michel Lapeyre; Jacques Tortochaux; Michel Rives; Mehdi Aghili; Sylvain Bourdin; François Lesaunier; Toufik Benassi; Claire Lemanski; Lionel Geoffrois; Antoine Lusinchi; Pierre Verrelle; Etienne Bardet; Morbize Julieron; Pierre Wibault; Monique Luboinski; Ellen Benhamou Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: James R Marshall; Clement Ip; Karen Romano; Gerald Fetterly; Marwan Fakih; Borko Jovanovic; Marjorie Perloff; James Crowell; Warren Davis; Renee French-Christy; Alexander Dew; Margerie Coomes; Raymond Bergan Journal: Cancer Prev Res (Phila) Date: 2011-08-16
Authors: Ralph Muecke; Lutz Schomburg; Michael Glatzel; Regina Berndt-Skorka; Dieter Baaske; Berthold Reichl; Jens Buentzel; Guenter Kundt; Franz J Prott; Alexander Devries; Guenther Stoll; Klaus Kisters; Frank Bruns; Ulrich Schaefer; Norman Willich; Oliver Micke Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-03 Impact factor: 7.038
Authors: Inas A Asfour; Maha M El-Tehewi; Manal H Ahmed; Mey A Abdel-Sattar; Nevine N Moustafa; Hany M Hegab; Omar M Fathey Journal: Biol Trace Elem Res Date: 2008-10-25 Impact factor: 3.738
Authors: Marwan G Fakih; Lakshmi Pendyala; William Brady; Patrick F Smith; Mary E Ross; Patrick J Creaven; Vladimir Badmaev; Joshua D Prey; Youcef M Rustum Journal: Cancer Chemother Pharmacol Date: 2007-11-08 Impact factor: 3.333
Authors: Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Elizabeth A Repasky; Anurag K Singh Journal: Oral Oncol Date: 2020-06-16 Impact factor: 5.337